ERBB2 and head and neck squamous cell carcinoma: Due to the lack of a well-recognized evaluation system, there is some controversy over HER2 clinical expression status in OSCC or HNSCC, limiting the application of HER2 or pan HER2 target therapy in this region [32–34].